"The US Food and Drug Administration (FDA) has approved diclofenac sodium injection (Dyloject, Hospira Inc), a proprietary nonsteroidal anti-inflammatory drug (NSAID) for the treatment of mild to moderate pain, and for the management of mod"...
The following serious adverse reactions are discussed elsewhere in the labeling:
Application-Associated Pain [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in clinical practice.
Across all controlled and uncontrolled trials, more than 1,600 patients have received Qutenza (capsaicin 8% patch) . A total of 394 patients received more than one treatment application and 274 patients were followed for 48 weeks or longer.
In controlled clinical studies, 98% of patients completed ≥ 90% of the intended patch application duration. Among patients treated with Qutenza (capsaicin 8% patch) , 1% discontinued prematurely due to an adverse event.
Controlled Clinical Studies
Common Adverse Reactions
Adverse events occurring in ≥ 5% of patients in the Qutenza (capsaicin 8% patch) group and at an incidence greater than in the control group were application site erythema, application site pain, application site pruritus and application site papules.
Table 1 summarizes all adverse reactions, regardless of causality, occurring in ≥ 1% of patients with postherpetic neuralgia in the Qutenza (capsaicin 8% patch) group for which the incidence was greater than in the control group. The majority of application site reactions were transient and self-limited. Transient increases in pain were commonly observed on the day of treatment in patients treated with Qutenza (capsaicin 8% patch) . Pain increases occurring during patch application usually began to resolve after patch removal. On average, pain scores returned to baseline by the end of the treatment day and then remained at or below baseline levels. A majority of Qutenza (capsaicin 8% patch) -treated patients in clinical studies had adverse reactions with a maximum intensity of "mild" or "moderate”.
TABLE 1: Treatment-emergent adverse reaction incidence (%)
in controlled trials in Postherpetic Neuralgia (Events in ≥ 1% of Qutenza (capsaicin 8% patch) -treated
patients and at least 1% greater in the Qutenza (capsaicin 8% patch) group than in the Control group)
|Body System Preferred Term|| Qutenza (capsaicin 8% patch) 60 minutes
(N = 622)
| Control 60 minutes
(N = 495)
|General Disorders and Administration Site Conditions|
|Application Site Erythema||63||54|
|Application Site Pain||42||21|
|Application Site Pruritus||6||4|
|Application Site Papules||6||3|
|Application Site Edema||4||1|
|Application Site Swelling||2||1|
|Application Site Dryness||2||1|
|Infections and Infestations|
|Skin and Subcutaneous Tissue Disorder|
Other Adverse Reactions Observed During the Clinical Studies of Qutenza (capsaicin 8% patch)
General Disorders and Administration Site Conditions: Application site urticaria, Application site paresthesia, Application site dermatitis, Application site hyperesthesia, Application site excoriation, Application site warmth, Application site anesthesia, Application site bruising, Application site inflammation, Application site exfoliation, Peripheral edema
Nervous System Disorders: Headache, Burning sensation, Peripheral sensory neuropathy, Dizziness, Dysgeusia, Hyperesthesia, Hypoesthesia
Respiratory, Thoracic and Mediastinal Disorders: Cough, Throat irritation
Skin and Subcutaneous Tissue Disorders: Abnormal skin odor
Read the Qutenza (capsaicin 8% patch) Side Effects Center for a complete guide to possible side effects
No clinical drug interaction studies have been performed.
Data from in vitro cytochrome P450 inhibition and induction studies show that capsaicin does not inhibit or induce liver cytochrome P450 enzymes at concentrations which far exceed those measured in blood samples. Therefore, interactions with systemic medicinal products are unlikely.
Last reviewed on RxList: 12/2/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Qutenza Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.